Amides as inhibitors for pyruvate dehydrogenase

Details Amides as inhibitors for pyruvate dehydrogenase Amides as inhibitors for pyruvate dehydrogenase

2005-04-12

2005-04-12

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S255010, C514S327000, C514S329000, C514S330000, C514S415000, C544S383000, C544S379000, C544S388000, C546S221000, C546S223000, C546S224000, C546S226000, C548S491000

Reexamination Certificate

active

06878712

ABSTRACT:
A compound of formula (I):wherein:Ring A is a nitrogen linked mono or bicyclic heterocyclic ring as defined within;R1and R2are independently C1-3alkyl optionally substituted by fluoro or chloro;or R1and R2together with the carbon atom to which they are attached, form a C3-5cycloalkyl ring optionally substituted by fluoro;R3is defined within; andn is 0-5; wherein the values of R3may be the same or different;or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.

REFERENCES:
patent: 4537618 (1985-08-01), Schurter et al.
patent: 5248693 (1993-09-01), Gerspacher et al.
patent: 5486515 (1996-01-01), Brown et al.
patent: 5510386 (1996-04-01), Empfield et al.
patent: 6369273 (2002-04-01), Butlin
patent: 6498275 (2002-12-01), Butlin et al.
patent: 1 228 355 (1987-10-01), None
patent: 0 002 309 (1979-06-01), None
patent: 0 002 892 (1979-07-01), None
patent: 0 040 932 (1981-12-01), None
patent: 0 079 191 (1983-05-01), None
patent: 0 096 002 (1983-12-01), None
patent: 0 100 172 (1984-02-01), None
patent: 0 253 500 (1988-01-01), None
patent: 0 253 503 (1988-01-01), None
patent: 0 524 781 (1993-01-01), None
patent: 0 617 010 (1994-09-01), None
patent: 0 625 511 (1994-11-01), None
patent: 0 625 516 (1994-11-01), None
patent: 2 278 054 (1994-11-01), None
patent: 9310094 (1993-05-01), None
patent: 9323358 (1993-05-01), None
patent: 9426739 (1994-11-01), None
patent: 9628151 (1996-09-01), None
patent: 9738124 (1997-10-01), None
patent: 9944618 (1999-09-01), None
patent: 9947508 (1999-09-01), None
patent: 9962506 (1999-12-01), None
patent: 9962873 (1999-12-01), None
patent: 0117942 (2001-03-01), None
patent: 0117955 (2001-03-01), None
patent: 0117956 (2001-03-01), None
Timmons et al. J. Clin. Invest., vol. 97, p. 879-883 (1996).*
Aicher et al., “(R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides are orally active inhibitors of pyruvate dehydrogenase kinase”, Journal of Medicinal Chemistry, American Chemical Society, vol. 42, No. 15, Jul. 1999, pp. 2741-2746, XP002122777.
Mann et al, Diverse mechanisms of inhibition of pyruvate dehydrogenase inhibitors, Biochim, Biophys. ACTA, 2000, 1480(1-2) XP000979112.
Aicher et al., “Secondary amides of (R)-3,3,3-Trifluoro-2-hydroxo-2-methylpropaionicacid as inhibitors of pyruvate dehydrogenase kinase”, J. Med. Chem., vol. 43, No, 2, Jan. 2000, pp. 236-249, XP002158429.
Bayles et al., “A Smiles Rearrangement Involving Non-Activated Aromatic Systems; the Facile Conversion of Phenols to Anilines”, Synthesis, 1977, vol. 1. pp. 33-34.
Bayles et al.,, “The Smiles Rearrangement of 2-Aryloxy-2-methylpropanamides. Synthesis of N-Aryl-2-hydroxy-2-methyl-propanamides”, Synthesis, 1977, vol. 1, pp. 31-33.
Bebernitz et al., “Anilides of (R)-Trifluoro-2-hydroxy-2-methylpropionic Acid as Inhibitors of Pyruvate Dehydrogenase Kinase”, J. Med. Chem., 2000, vol. 43, No. 11, pp. 2257-2266.
Empfield et al., “4-sulfonamidoanilide Tertiary Carbinols: A Novel Series Of Potassium Channel Openers”, Bioorg Med. Chem. Letters, 1997, vol. 7, No. 7, pp. 775-778, XP004136128s e table I, compounds e, f.
Fenwick, “The Synthesis of 2,2-Bis(Trifluoromethyl)Benzopyran Derivatives: A New Route to an Import Class of Postassium Channel Activators”, Tetrahedron Letters, vol. 34, No. 11, 1993, pp. 1993.
Furr et al., “A Novel Non-Steroidal, Peripherally Selective Antiandrogen”, J. Endrocrinol., 1987, vol. 113 (3), R7-R9.
Glen et al., Structure-Activity Relationships among Non-steriodal Antiandrogens, Third SCI-RSC Medicinal Chemistry Symposium, 1986, vol. 55, pp. 345-361.
Grant et al., “Anilide Tertiary Carbinols: A New Structural Class Of Potent Potassium Channel Openers”, Bioorg. Med. Chem. Lett., 1993, vol. 3 (12), pp. 2723-2724.
Howe et al., “Zeneca ZD6169: A Novel KATPChannel Opener with in Vivo Selectivity for Urinary Bladder”, J. Pharmacol. Exp. Ther. 1995, vol. 274 (2), pp, 884-890.
Jackman et al., “Studies in the Field of Diuretics”, J. Pharm. and Pharmacol., vol. 12, 1960, pp. 648-655; Chemical Abstracts, vol. 55, No. 9, May 1, 1961, Columbus, Ohio, US; abstract No. 8336a, XP002107578 see abstract, col. 8336, lines 8-9 &.
Li et al., “Zeneca ZD6169 and Its Analogs from a Novel Series of Anilide Tertiary Carbinols: in vitro KATPChannel Opening Activity in Bladder Detrusor”, Pharmacology, 1995, vol. 51, pp. 33-42.
Morris et al., “Hydrogen Bonding Parameters In The S.A.R. of Non-Steroidal Anti-Androgens”, Pharmacol. Libr., 1987, vol. 10, pp. 204-206.
Morris et al., “Non-Steroidal Antiandrogens. Design of Novel Compounds Based on an Infrared Study of the Dominant Conformationand Hydrogen-Bonding Properties of a Series of Anilide Antiandrogens”, J. Med. Chem. 1991, vol. 34, pp, 447-455.
Ohnmacht et al., N-Aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATPPotassium Channel Openers. Modifications on the Western Region, J. Med. Chem., 1996, vol. 39 (23), pp. 4592-4601.
Russell, “Crystal Receptor Models In Medicinal Chemistry: Application To The Generation of Highly Potent Potassium Channel Openers”, Bioorg. Med. Chem. Lett. 1996, vol. 6 (7), pp. 913-918.
Tenthorey et al.; “New Antiarrhythmic Agents. 3. Primary β-Amino Anilides”, J. Med. Chem. 1979, vol. 22 (10), pp. 1182-1186.
Trivedi et al., “K-Channel Opening Activity of ZD6169 and Its Analogs: Effect on86Rb Efflux and3H-1075 Binding in Bladder Smooth Muscle”, Pharmacology, 1995, vol. 50 (6), pp. 388-397.
Tucker et al., “Nonsteroidal Antiandrogens. Synthesis and Structure-Activity Relationships of 3-Substituted Derivatives of 2-Hydroxypropionanilides”, J. Med. Chem., 1988, vol. 31, pp. 954-959.
Tucker et al., “Resolution of the Nonsteriodal Antiandrogen 4′-Cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3′-(trifluoromethyl)- propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer”, J. Med. Chem. 1988. vol. 31 (4), pp. 885-887.
Wakeling et al., “Receptor Binding And Biological Activity Of Steriodal and Nonsteriodal Antiandrogens”, J. Steriod Biochem., 1981, vol. 15, pp. 355-359.

Affiliated with

Also associated with

Rating

Amides as inhibitors for pyruvate dehydrogenase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amides as inhibitors for pyruvate dehydrogenase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amides as inhibitors for pyruvate dehydrogenase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3366656